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Abstract
Background: Except for testicular cancer and Hodgkin’s disease, baseline data on semen quality in case of cancers
as well as systemic pathologies of the young adult are scarce or based on low sample size.
Methods: Semen quality in patients having testicular cancer (TGCT, n = 2315), Hodgkin’s disease (HD, n = 1175),
non-Hodgkin’s lymphoma (NHL, n = 439), leukemia (L, n = 360), sarcoma (S, n = 208), brain tumour (BT, n = 40),
Behcet’s disease (Behcet’s, n = 68) or multiple sclerosis (MS, n = 73) was studied and compared to that of 1448 fertile
men candidates for sperm donation (CSD) and 208 partners of pregnant women (PPW). All samples were studied
following the same methodology in a single laboratory. Post freezing and thawing semen characteristics were also
studied.
Results: The percentage of normozoospermic men was only 37 % for L patients and lower than 60 % for TGCT,
NHL, S and BT. The level of sperm production was differently decreased according to pathologies, the median total
sperm count in TC and L patients being four times lower (p < 0.01 when compared to CSD and PPW). The lowest
percentage of progressively motile spermatozoa was found for L and BT patients (both, p < 0.01 compared to CSD
and PPW). The percentage of morphologically normal spermatozoa was also reduced in cancer patients, especially
in BT patients. Progressive motility after thawing in patients was about half that observed among candidates for
sperm donation. In almost half of the semen of patients with testicular cancer or leukemia, the total number of
motile spermatozoa per straw was less than 0.5 × 106 compared to 4.3 × 106 in CSD.
Conclusions: The present data confirm on large series the deleterious impact of various cancers of the young adult
on semen quality, establishing thus baseline data for future studies. Owing to the post-thaw quality of the frozen
straws, future fertility projects for the majority of the patients studied (in case there is no post-treatment recovery of
spermatogenesis) should necessitate an ICSI to provide the best chance of paternity whatever the fertility check-up
in the female partner.
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French language Abstract
Contexte: En dehors du cancer du testicule et de la maladie de Hodgkin, les données de la littérature sur la qualité
du sperme dans le cas de cancers et de maladies systémiques du jeune adulte sont rares et le plus souvent basées
sur de faibles effectifs.
Méthodes: La qualité spermatique de patients ayant un cancer du testicule (TGCT, n = 2 315), une maladie de
Hodgkin (HD, n = 1175), un lymphome non Hodgkinien (LNH, n = 439), une leucémie (L, n = 360), un sarcome
(S, n = 208), une tumeur cérébrale (BT, n = 40), une maladie de Behcet (Behcet, n = 68) ou une sclérose en plaque
(MS, n = 73) a été étudiée et comparée à celle de 1448 hommes féconds candidats au don de spermatozoïdes
(CSD) et 208 partenaires de femmes enceintes (PPW), utilisant la même méthodologie dans un seul laboratoire.
Les caractéristiques du sperme après dégel ont également été analysées.
Résultats: Le pourcentage de spermes normozoospermiques était seulement de 37 % chez les patients L, et <
60 % pour les patients TGCT, NHL, S et BT. La production spermatique était diminuée dans la plupart des
pathologies, le nombre total spermatozoïdes par éjaculat des patients TC et L étant 4 fois plus faible (p <0,01 par
rapport aux hommes féconds). Le plus faible pourcentage de spermatozoïdes mobiles a été trouvé pour les
patients L et BT (p <0,01 par rapport aux hommes féconds). Une diminution du pourcentage de spermatozoïdes
normaux a aussi été observée chez les patients cancéreux, particulièrement pour les patients BT. La motilité
progressive après décongélation des patients était diminuée de moitié par rapport aux candidats pour le don de
sperme. La médiane du nombre total de spermatozoïdes mobiles par paillette était inférieure à 0,5 × 106 pour
TGCT et L contre 4,3 × 106 pour les candidats au don.
Conclusion: Les données présentées obtenues sur de grandes séries rarement publiées constituent des données
de référence pour de futures études. Dans le cas d’une utilisation de paillettes en AMP, l’ICSI sera nécessaire dans la
majorité des cas.
Mots clés: Cancer, Maladie auto-immune, Qualité du sperme, Conservation du sperme, Congélation, Aide médicale
à la procréation
Background
Advancements in early diagnoses and new treatments of
cancer have greatly contributed to a high survival rate in
the last decades [1]. With the increasing number of young
adults survivors of cancer, long-term quality of life has be-
come an important issue, especially preservation of repro-
ductive potential [2]. The same issues are observed for
men presenting severe immunological diseases, such as
multiple sclerosis. Available literature about semen quality
of men concerned with those chronic tumoral or systemic
diseases is usually scarce, often based on low sample sizes
of patients studied. Studies based on high number of pa-
tients have been recently reported [3, 4], especially about
semen quality of testicular cancer and Hodgkin’s disease
patients, the most frequent cancers in young men [5, 6].
The aggregation of different pathologies in heterogeneous
groups (such as, ‘hematological cancer’, ‘other cancers’ etc.)
is one limitation of several studies in the field because
these pathologies have different origins, may have different
impacts on individuals and, maybe, a different effect on
the testis and the male reproductive tract. Another fre-
quent limitation of previous reports is the absence of ref-
erence population in order to appreciate the magnitude of
the alterations in semen quality related to the diseases.
Testicular and post-testicular disorders are well-
known side effects of anti-tumoral treatments and other
therapies used for immunological diseases [7]. These al-
terations may be transient, but also long lasting [8, 9].
The middle term and long term impact of these treat-
ments is unpredictable in most cases, thus, sperm cryo-
preservation remains the cornerstone of male fertility
preservation in patients treated for these pathologies
[10, 11]. However, little has been reported on the prac-
tical usefulness of sperm banking according to the vari-
ous indications.
The objectives of the present study, based on a 30-
year period in sperm banking for cancer and systemic
disease patients, are (i) to compare the sperm character-
istics in patients and healthy fertile men, and, (ii) to as-
sess the feasibility of using the cryopreserved semen
samples in the various pathologies studied according to
currently available Assisted Reproductive Technologies.
Methods
The present study is a retrospective observational study.
Men under study
Two categories of men were studied : (i) patients with vari-
ous types of cancer or auto-immune diseases who were re-
ferred for sperm cryopreservation before a potentially
gonadotoxic treatment to the former Bicêtre University
Hospital sperm bank (Centre d’Etude et de Conservation
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des Œufs et du Sperme humains, CECOS) transferred to
the Cochin university hospital in 1994 (study period:
1974–2003), and, (ii) two populations of healthy fertile
men recruited in the same sperm bank during the same
time period, corresponding to a population of 1448 candi-
dates for sperm donation (CSD) (<45 years old and being
fathers, as required by French law) and another group of
208 healthy men partners of pregnant women (PPW) vol-
unteers to participate in a study evaluating the impact of
environmental factors on semen quality and time to
pregnancy.
Pathologies requiring potentially gonadotoxic treat-
ments, and therefore sperm banking, were testicular
germ cell tumour cancer (TGCT, n = 2315) including
seminoma and non-seminoma tumours, the vast major-
ity of patients being referred before orchidectomy,
Hodgkin’s disease (HD, n = 1175), non-Hodgkin’s lymph-
oma (NHL, n = 439), leukemia (L, n = 360) including
both acute and chronic forms, sarcoma (S, n = 208) in-
cluding bone and soft tissue sarcoma, brain tumour (BT,
n = 40) of various histological nature, and, two systemic
diseases, Behcet’s disease (Behcet’s, n = 68) and multiple
sclerosis (MS, n = 73). Patients with a history of previous
gonadotoxic treatment (<5 %) were excluded. Age at
referring, and fertility history were recorded.
Semen analysis
All semen samples were collected by masturbation in the
laboratory. A period of sexual abstinence of 3–5 days be-
fore semen collection was recommended to all patients
and healthy men, and the accurate period of sexual abstin-
ence in days was recorded at the time of semen collection.
Standardized procedures for routine semen analysis were
used throughout the study period. Briefly, semen samples
were incubated at 37 °C and analysed within one hour.
Seminal volume was determined by weighing. Sperm con-
centration (x106 per ml) was assessed using a haemocyto-
metric method. The total number of spermatozoa per
ejaculate (x106), grossly reflecting testicular sperm pro-
duction, was calculated as the product of sperm concen-
tration by the volume of seminal fluid. The percentage of
progressively motile spermatozoa was assessed at 37 °C at
x100 and x400 magnification with phase optics in four to
six fields chosen at random, in two preparations, the mean
value being reported. The percentage of morphologically
normal spermatozoa was assessed according to the classi-
fication of David [12], slightly modified in the late 1990s
[13], the criteria used for scoring the normal spermatozoa
remaining the same considering borderline aspects as
normal, an equivalent to the ‘liberal’ WHO criteria [14].
Sperm cryopreservation
Except for partners of pregnant women, all semen samples
were frozen according to a standardized slow-freezing
method as previously reported (see for example [15]).
Briefly, each semen sample was diluted into a cryoprotect-
ant medium and this preparation was distributed into
French straws. Freezing was carried out in liquid nitrogen
vapours using an automatic freezer with a programmed
cooling rate. The straws were directly plunged into liquid
nitrogen at the end of the freezing process. In order to
evaluate the tolerance to freezing, one straw per sample
was thawed to assess the post-thaw progressive motility in
order to calculate the recovery rate in progressive motile
spermatozoa (corresponding to the ratio of post thaw mo-
tility to pre freeze motility, expressed in %) and the total
number of progressive motile spermatozoa per straw
(NMSPS, accounting for straw volume, dilution ratio,
sperm concentration and post thaw motility, ×106). Of note,
both the type of straw and the cryoprotectant have been
changed during the 1990s: 0.30 ml high security French
straw has replaced the classical 0.25 ml French straw and, a
HEPES buffered - ready-to-use - freezing medium has re-
placed the glycerol-egg yolk-citrate medium used before.
However, before these changes it was verified that the
sperm characteristics after freezing and thawing were not
significantly different with the new material and medium in
comparison to the classical ones.
Statistical analysis
In this study, only the first semen sample collected either
in patients or fertile men was considered for descriptive
and comparative statistical analyses. All statistics were
performed with the BMDP statistical software (Statistical
Solutions, Cork, Ireland). Quantitative values were
expressed as mean ± standard deviation and/or median
with interquartile (IQ) ranges. The percentage of normo-
zoospermic men according to WHO reference values
(≥39 × 106 per ejaculate and ≥32 % of progressive motility
[16], excluding morphology) was calculated in order to ap-
preciate the extent of men with an acceptable fertility po-
tential for each pathology studied in comparison to fertile
men. In addition, the similarity of the mean values for
various semen characteristics between all groups of pa-
tients and healthy men studied was assessed by a one-way
analysis of variance (BMDP 7D subroutine), taking un-
equal variances into account (Brown-Forsythe test) when
necessary. When the null hypothesis was rejected, post-
hoc Tukey tests were used for pair-wise comparisons be-
tween patients and healthy fertile men.
Semen collection failure and azoospermia rates were re-
corded in order to assess the feasibility of sperm freezing
in the various groups of pathologies. To discuss the poten-
tial use of the frozen sperm samples through Assisted
Reproductive Technologies (ART), patients were stratified
according to their pathology and to NMSPS categories,
defined by a possibly minimal NMSPS required for each
strategy: ≥ 4x106 for Intra-Uterine Insemination (IUI)
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[17], in the range < 4 × 106 and ≥2 × 106 for conventional
In Vitro Fertilization (IVF) and < 2 × 106 for Intra Cytoplas-
mic Sperm Injection (ICSI).
Ethical approval
The study was approved by the Cochin University
Hospital for the three groups of men studied (CSD, PPW
and cancer patients). Informed consent was obtained from
all participants.
Results
Mean age of the patients was 28 ± 7 years old, 12.9 % of
the patients being 20 years old or younger. Thirty seven
percent of all patients (n = 1645) were childless. Table 1
summarizes the age and percentage of childless patients
for the various pathological conditions studied.
Semen quality
Median sexual abstinence was in the range of a mini-
mum of 2 days and a maximum of 7 days [18] while
about one quarter of the patients in all the pathologies
studied had a longer period of sexual abstinence than
one week (data not shown). Figure 1 presents the per-
centage of normozoospermic patients in the various
pathological groups and healthy men according to WHO
2010 reference values [16]. Normozoospermia was ob-
served for only half of TGCT patients, and 40 % or
lower for L and BT patients, compared to more than
93 % in both groups of healthy fertile men.
A statistically significant lower sperm concentration, total
sperm count, progressive motility and normal morphology
was observed for most of the pathological groups of men
studied in comparison to both groups of healthy fertile
men (Fig. 2 and Table 2). Overall, TGCT and leukemia pa-
tients had the lowest semen characteristics and patients
with a systemic disease had the best semen quality among
all pathologies studied. Notably, the level of sperm produc-
tion in TGCT and leukemia patients was about one quarter
of the level found in CSD and PPW.
Clinical considerations
What was the proportion of men referred for sperm
cryopreservation who could not effectively benefit from
this procedure? This essentially concerned men who
could not succeed in collecting a semen sample and
men with azoospermia at the time of their referral. Sam-
ple collection failure concerned 5.7 % of men, varying
from 2.9 % in Behcet’s disease to 17.8 % in multiple
sclerosis. Overall, azoospermia was diagnosed for 5.7 %
of men at the time of their referral, the highest rate be-
ing for leukemia patients (13.2 %) (Fig. 3).
Do the studied pathologies affect tolerance to freezing
and thawing in comparison to healthy men (CSD)? The
post thaw progressive motility, the motility recovery rate
and the number of motile sperm per straw were signifi-
cantly lower for the vast majority of patients and par-
ticularly for TGCT and L patients (Table 3).
What were the theoretical possibilities to use banked
sperm through current ART? Figure 4 summarizes the
percentage of men who may benefit from IUI, IVF or
ICSI according to the quantity and quality of spermato-
zoa within straws when grossly estimated by the number
of progressively motile sperm per straw (NMSPS). Overall,
an ICSI would be the required ART approach for more
than 50 % of all patients, with the lowest need in Behcet
patients (42 %) and the highest in TGCT patients
(85 %), the theoretical use in case of CSD being 18 %. In
contrast, simple IUI may be proposed in only 10 to 40 %
of cases depending on the pathological condition versus
54 % in CSD patients.
Discussion
To our knowledge, this study presents the largest series
of patients referred for sperm cryopreservation before
potentially gonadotoxic treatment, thus providing sound
data on semen quality for various pathological condi-
tions. The extent of poor semen quality is underlined
thanks to the calculation of the percentage of normo-
zoospermia as well as the comparison with the level of
semen quality in two large groups of healthy fertile men.
In addition, our study provides baseline data in cases of
brain tumour, Behcet’s disease and multiple sclerosis,
three pathological conditions for which possible impact
on semen quality has rarely been studied.
The possible direct or indirect role of the pathologies
studied on the level of semen quality is briefly discussed
below. Then, we discuss the feasibility of sperm banking
in the various pathologies as well as its theoretical use
for a parental project when a long lasting post-treatment
azoospermia is observed.
Semen quality
Although sperm alterations most commonly occur as a
result of treatment with gonadotoxic agents, they could
also be observed before treatment, and may depend on
cancer type. Moreover, only few studies have compared
Table 1 Age and fertility status of patients according to the
various pathological conditions studied
TGCT HD NHL L S BT Behcet MS
n 2315 1175 439 360 208 40 68 73
Age (year, median) 28.8 26 28.8 27.5 23.1 28.2 29.7 30.3
%≤ 20 year-old 7.1 19.1 15.7 20.6 35.6 25 5.9 5.5
% Childless 53 61.3 54.1 54.1 75.4 72.5 39.7 24.7
TGCT testicular germ cell tumour, HD Hodgkin’s disease, NHL non-Hodgkin’s
lymphoma, L leukemia, S sarcoma, BT brain tumour, Behcet Behcet’s disease,
MS multiple sclerosis
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semen quality in different pathologies and healthy volun-
teers [19–21].
Various pathophysiological hypotheses could be raised
to explain spermatogenesis impairment in a context of
cancer. Those include direct tumour effects on testis
and male reproductive tract, but also indirect impact
with endocrine disturbances, or nutritional, autoimmune
and systemic effects of cancer (see [22] for review).
Sperm chromatin assay (SCSA) [23, 24] revealed sperm
DNA damage due to pathology when compared to
healthy fertile men. Moreover, in our study, a decrease
in seminal volume was also observed for cancer or im-
munological disease patients, whereas the abstinence
delay tends towards being longer than in fertile groups.
Because semen volume depends on the contraction of
the accessory glands which is influenced by the level of
excitement during semen collection, these patients not
being in an optimal psychological condition, this may
Fig. 1 Percentage of normozoospermic men in the various pathological conditions and the two groups of healthy fertile men (CSD and PPW)
Fig. 2 Box plot displaying the 10th, 25th, 50th, 75th, and 90th percentile values and the extreme 5th and 95th percentiles (circles) of sperm
concentration, total sperm count, progressive sperm motility and normal sperm morphology according to the various pathological conditions.
Distributions in healthy fertile men (CSD and PPW) are presented for comparison (see Table 2 for statistical comparisons)
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Table 2 Semen characteristics in the various pathological groups of men studied and comparisons with the two groups of healthy fertile men
CSD PPW TGCT HD NHL L S BT Behcet MS F p-value
n 1448 208 2315 1175 439 360 208 40 68 73 - -
Seminal volume (ml) 3.8 ± 1.8a 4.2 ± 2.0 3.7 ± 2.0 *** 3.2 ± 1.9**,**** 3.1 ± 1.8**,**** 2.9 ± 1.7**,**** 3.2 ± 1.8**,**** 3.5 ± 1.8 3.2 ± 1.9 **** 3.2 ± 1.9*,**** 19 <0.0001
3.5 (2.5–4.8)b 3.9 (2.7–5.2) 3.4 (2.3–4.8) 2.9 (1.9–4.1) 2.9 (1.9–4.1) 2.6 (1.7–3.9) 2.9 (2.0–4.3) 3.1 (2.1–4.4) 2.8 (1.5–4.6) 2.9 (1.7–4.5)
Sperm concentration
(×106/ml)
99.1 ± 73.8 94.2 ± 71.8 36.1 ± 48.5**,**** 79.4 ± 103.1** 81.2 ± 91.7** 63.0 ± 96.3**,**** 72.8 ± 83.2** 86.7 ± 118.4 116.6 ± 125.8 98.3 ± 87.4 118 <0.0001
82.4 (48.4–133.0) 74.0 (40.6–125.0) 19.6 (5.4–48.8) 52.0 (18.1–104.0) 55.6 (18.0–115.2) 25.6 (1.6–88.0) 44.7 (15.9–96.5) 56.8 (9.8–94.6) 83.2 (27.6–167.7) 74.6 (30.6–131.7)
Total sperm count
(×106)
362 ± 328 383 ± 350 127 ± 174**,**** 250 ± 388**,**** 245 ± 289**,**** 179 ± 293**,**** 233 ± 307**,**** 287 ± 394 357 ± 428 312 ± 439 89 <0.0001
281 (152–486) 291 (153–488) 64 (16–178) 147 (45–323) 160 (38–324) 71 (4–209) 124 (39–316) 140 (34–331) 221 (63–419) 159 (105–357)
Progressively motile
sperm (%)
65 ± 12**** 50 ± 13** 43 ± 19**,**** 47 ± 20** 43 ± 21**,**** 33 ± 21**,**** 41 ± 19**,**** 27 ± 17**,**** 47 ± 18** 43 ± 19**,*** 300 <0.0001
65 (60–75) 48 (42–58) 45 (30–56) 50 (35–60) 45 (30–60) 35 (15–50) 40 (30–55) 30 (10–40) 50 (35–60) 45 (30–60)
Morphologically
normal sperm (%)
61 ± 13 **** 49 ± 15** 34 ± 19**,**** 41 ± 21**,**** 37 ± 20**,**** 29 ± 18**,**** 31 ± 20**,**** 20 ± 15**,**** 36 ± 22**,**** 41 ± 16**,**** 313 <0.0001
62 (53–70) 52 (39–61) 33 (19–48) 42 (25–58) 37 (21–52) 29 (15–41) 28 (14–46) 17 (7–32) 33 (16–59) 40 (30–54)
For all pathological conditions, differences between groups of men were investigated by one-way analysis of variance. For pair-wise comparisons, post hoc Tukey tests were carried out, with: * p < 0.05 and ** p < 0.01
in comparison to CSD and ***p < 0.05 and ****p <0.01 in comparison to PPW
aMean ± SD; bMedian (IQ range)
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certainly explain most of the observed low semen vol-
umes which simply reflect a lower level of excitement.
However, other additional factors such as an hypoandro-
genisation for some of the patients cannot be ruled out.
Some differences can be noted according to the type of
pathology. For testicular cancer, the majority of authors
suggested altered semen parameters, usually sperm con-
centration and count [3, 4, 21, 25–28], the results being
more controversial for motility and morphology. In our
series, we observed significantly decreased sperm concen-
tration, count, motility and morphology when compared
to semen parameters of both groups of fertile healthy
men. Only 50.9 % of men with testicular cancer presented
normozoospermia when WHO 2010 reference thresholds
were applied. Williams et al. found that 37 % of men with
testicular cancer were normozoospermic using previous
WHO 1999 criteria [21] and Hotaling et al. reported that
only 59 % of TGCT patients had a total motile sperm
count of more than five million [20]. However, both of
these studies used low sample sizes and other reference
values, making results difficult to compare. In addition to
common mechanisms in all types of cancer, pre-existing
defects in germ cells as part of testicular dysgenesis syn-
drome could also be involved in case of testicular cancer
[29], as suggested by frequent histological modifications
that are found in the controlateral testis [30].
For haematological diseases, most of studies revealed
impaired sperm parameters. However, results are very
difficult to compare because of the wide variety of
diseases, leading either to small sample sizes in the stud-
ies [20, 21, 27, 28] or to a combination of different path-
ologies [3, 4, 19]. In our series, we observed moderate
but significant decreased sperm concentration, count,
motility and morphology in patients presenting lymph-
omas; 65.1 and 59.5 % of men had normozoospermia in
cases of Hodgkin’s lymphoma or non Hodgkin’s lymph-
oma, respectively. On the contrary, a drastic decrease of
motility and morphology were observed for men pre-
senting leukemia, and only 36.9 % presented normozoos-
permia. Altered general state, hyperthermia (frequently
observed during lymphomas) or testicular infiltration (as
in acute leukemia), could be additional pathophysio-
logical mechanisms responsible for the impaired sperm-
atogenesis during haematological diseases [6, 31].
Semen quality may be expected to be better in case of
chronic forms of leukemia than in case of acute
leukemia due to the possible severe deterioration of the
general health conditions and the impact of high fever
episodes in this form of leukemia. Because we had no
mean to a posteriori separate both forms of leukemia
we could not provide baseline data for each subcategory.
For other solid malignant diseases, literature is scarce,
usually showing normal or subnormal sperm parameters
[20, 21, 26, 27], but with very small sample sizes (some
with a maximum of ten). For men presenting sarcoma,
a moderate decrease in all semen parameters was ob-
served in our series. On the contrary, for men presenting
cerebral tumours, sperm concentration and counts were
Table 3 Post thaw sample characteristics according to the various pathologies studied in reference to the CSD healthy group
CSD TGCT HD NHL L S BT Behcet MS F p-value
n 1448 2315 1175 439 360 208 40 68 73 _ _
Post-thaw motility (%) 40 ± 14 21 ± 15* 24 ± 16* 23 ± 16* 17 ± 15* 22 ± 15* 17 ± 14* 26 ± 15* 23 ± 17* 223 <0.0001
Motility recovery rate (%) 60 ± 17 44 ± 25* 46 ± 25* 46 ± 25* 40 ± 28* 47 ± 26* 53 ± 29 52 ± 21 51 ± 27* 73 <0.0001
NMSPS (×106) 4.75 ± 3.21 1.26 ± 1.80* 2.78 ± 3.44* 2.54 ± 2.86* 1.80 ± 3.12* 2.06 ± 2.76* 4.32 ± 6.96 4.59 ± 5.90 2.75± 2.62* 156 <0.0001
Number of straws
(median)
_ 21 19 20 15 18 15 20 23 _ _
For all pathological conditions, differences between groups of men were investigated by one-way analysis of variance. For pair-wise comparisons, post hoc Tukey
tests were carried out, with: *p < 0.01 in comparison to CSD
Fig. 3 Percentage of patients with semen collection failure (a) and azoospermia (b)
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comparable to those of healthy fertile men, whereas mo-
tility and morphology were drastically reduced.
Finally, little is known about semen parameters of men
presenting severe systemic diseases such as Behcet’s dis-
ease or multiple sclerosis. Altered semen parameters
were pointed out in the only available study comparing
68 men with multiple sclerosis to 48 healthy volunteers
[32]. For Behcet’s disease, impaired sperm production
was suggested [33]. In our series, we observed moderate
alterations in semen parameters for both groups. About
70 % of men presented normozoospermia according to
WHO 2010 reference values.
Clinical considerations
There is a number of barriers to sperm banking. One
can ask what is the proportion of men actually referred
to a sperm bank (who probably do not represent the ma-
jority of men of reproductive age likely to be exposed to
gonadotoxic treatment) who could effectively benefit
from this procedure?
In our series, failure to collect a sperm sample was ob-
served in 5.7 % of men, slightly higher than in other
studies with about a 3 % collection failure rate [3, 4].
This difference may be explained by the absence in pre-
vious publications of populations more exposed to col-
lection failure, such as men with brain tumours,
sarcoma or multiple sclerosis. For these pathological
conditions, semen collection failure could be related to
stress, but also to severe illness with very impaired gen-
eral health (especially in leukemia or brain tumour pop-
ulations), sexual inexperience (especially for very young
adults, as in a sarcoma population), or neurological al-
terations (as seen in men with multiple sclerosis). Azoo-
spermia was observed in 5.7 % of all men, being
different according to different pathologies and ranging
from 0 % in brain tumours to 13.2 % in leukemia. In
leukemia cases, literature showed conflicting results,
with azoospermia ranging from 0.8 [4] to 24 % [27], in-
cluding 12.5 % [28]. Those differences may be due to
small sample sizes, making results difficult to compare.
In testicular cancer, we observed a rate of azoospermia
of 5.0 %, mostly comparable to previously published re-
sults in lower sample sizes [3, 4, 19].
The question of the difference in the tolerance of the
spermatozoa to the processes of freezing in liquid nitro-
gen vapours and subsequent thawing to ambient
Fig. 4 Possible ART strategies according to the pathologies studied and the number of progressive motile sperm per straw (NMSPS; ×106). It is
assumed that there are a sufficient number of stored straws and the fertility check-up in the female partner is normal
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temperature in patients with various cancers compared
to other groups of men has rarely been studied [34]. In
our study we observed a reduced progressive motility re-
covery in all groups, except brain tumours and immuno-
logical diseases, when compared to fertile candidates for
sperm donation. Our results concur with Caponecchia
et al. who found that the percentage of surviving sperm
cells was significantly lower in oncologic groups of men,
especially in a group of men having leukemia, than in a
fertile group (32.1 and 50.1 %, respectively) [19]. On the
contrary, Agarwal et al. suggested that there was no add-
itional loss of semen quality after thawing beyond that
to be expected from any semen cryopreservation [35].
This overall decrease in the motility recovery rate con-
tributes to the constitution of straws with significantly
lower NMSPS for men presenting testicular cancer,
haematological disease, sarcoma or Behcet’s disease,
when compared to fertile sperm donors. Beyond discus-
sion about minimal NMSPS required for ART [36, 37],
when evaluating the theoretical use of those straws,
decreased NMSPS in cancer patients leads to a less
frequent use of IUI and a more frequent use of IVF
with or without ICSI, regardless of the female fertility
check-up or the number of available straws. For a
small number of cases, no motile sperm cells were
observed post-thawing, making the use of the stored
semen samples uncertain, even for an ICSI attempt.
In those situations, the hypo-osmotic swelling test
(HOS-test) on a frozen and thawed straw constitutes
a very useful adjunct to ascertain if an ICSI attempt
may be programmed [38].
Conclusions
Our study, distinguished by its high semen sample size,
provides strong evidence that most of the pathological
conditions we examined seriously affect sperm produc-
tion and quality. However, due to its descriptive nature,
it does not offer explanations on the causal links or
modes of action, so more research in the field remains
needed. Despite the impact of the diseases considered in
the study on semen quality at the time when the patients
were referred to the sperm bank, spermatozoa may be
cryopreserved for the vast majority of referred men. This
provides opportunity for future paternity in cases of
post-treatment definitive azoospermia due to different
ART techniques, especially ICSI, which has significant
success rates even when initial levels of sperm produc-
tion and quality or sperm survival rates are low. While
post-treatment recovery in sperm production is often
found, depending on type of treatment, age and individ-
ual factors, sperm cryopreservation before any possibly
gonadotoxic therapy remains the gold standard for fertil-
ity preservation. This preventive care should be pro-
posed to all patients concerned.
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